|
Full Length
Research Paper
|
|
Efficacy and safety profile of moxifloxacin in treatment of
urogenital system infections: A meta-analysis of randomized
controlled trials
Yanping Mu1, Jinyu Huang2, Ruilin Liu3,
Xun Deng1, Liqing Wang1, Ping Fang4,
Meidan Wei1, and Yong Wang1*
1Department of Clinical
Pharmacology, Zhujiang Hospital, Southern Medical
University, Guangzhou 520282, China.
2Department of Stomatology，Zhujiang Hospital,
Southern Medical University, Guangzhou 520282, China.
3hujiang Hospital, Southern
Medical University, Guangzhou 520282, China.
4Department of Urology,
Zhujiang Hospital, Southern Medical University, Guangzhou
520282, China.
*Corresponding author: E-mail:
ywang43555@sina.com.
Accepted 26 March, 2012 |
|
|
|
Abstract |
|
|
This meta-analysis was performed to evaluate the
efficacy and safety profile of moxifloxacin in
treatment of urogenital system infections.
PubMed, EMBASE, Science Direct,
ClinicalTrials.gov, Cochrane Central Register of
Controlled Trials, CBM (Chinese Biomedical
Literature Database), CNKI (Chinese National
Knowledge Infrastructure), Wan Fang Data and VIP
INFORMATION were searched from January 1999 to
May 2011 to comprehensively collect randomized
controlled trials (RCTs) that compared
moxifloxacin with conventional antibiotics
therapy in patients with urogenital system
infections. Clinical cure rates, clinical
effective rates, pathogens eradication rates and
incidence of adverse drug reactions were pooled
using meta-analysis performed by Review Manager
5.1 software. Relative risk (RR) and 95%
confidence interval (95%CI) were calculated in a
random-effects model or in a fixed-effects
model. Twenty-two trials including a total of
3940 patients were included for meta-analysis.
The results of meta analysis showed that
clinical cure rates, clinical effective rates
and pathogens eradication rates of moxifloxacin
were higher than conventional therapy [RR =
1.08, 95%CI (1.02, 1.14), P = 0.008; RR = 1.09,
95%CI (1.04, 1.14), P = 0.0005; RR = 1.04, 95%CI
(0.99, 1.09), P = 0.08]; the incidences of
adverse drug reactions between moxifloxacin and
control group were not statistically significant
[RR = 0.88, 95%CI (0.72, 1.06), P = 0.17]. In
three large studies of pelvic inflammatory
disease (PID) patients, no statistically
significant difference was found between
moxifloxacin monotherapy group and control group
about clinical cure rates, microbiological
success rates and the incidences of adverse drug
reactions [RR = 0.98, 95%CI (0.95, 1.02), P =
0.33; RR = 1.06, 95%CI (0.96, 1.16), P = 0.25;
RR = 0.85, 95%CI (0.68, 1.05), P = 0.13].
Moxifloxacin can be suggested as the regimen of
choice for treatment of urogenital system
infections.
Key words:
Meta-analysis, moxifloxacin, efficacy, urogenital system
infections, pelvic inflammatory disease. |
